MedTrace Logo

Parent Education About Human Papillomavirus (HPV)

NCT07447245 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2026-08-10

No results posted yet for this study

Summary

Human papillomavirus (HPV) vaccination is an effective strategy for preventing HPV-related diseases; however, parental knowledge and vaccination intention may influence vaccine uptake among children and adolescents. This randomized controlled trial evaluated the effect of a Health Belief Model (HBM)-based parent education intervention on HPV knowledge and HPV vaccination intention among parents of children aged 9-14 years.

A total of 64 parents were enrolled and randomly assigned to an intervention group (n=32) or a control group (n=32). Following baseline assessment, the intervention group received a single, approximately 40-minute, face-to-face, nurse-led educational session based on the constructs of the Health Belief Model. The control group received no educational intervention during the five-week comparison period.

HPV knowledge and vaccination intention were assessed at baseline and five weeks later. After completion of the five-week assessment, the control group received the same educational session for ethical reasons.

Conditions

  • HPV (Human Papillomavirus)-Associated

Interventions

BEHAVIORAL

Behavioral: Health Belief Model-Based HPV Education

Participants assigned to the intervention group received a single, face-to-face, nurse-led educational session based on the Health Belief Model after completion of the baseline assessment. The approximately 40-minute session addressed HPV transmission, HPV-related cancers, HPV vaccination, vaccine effectiveness, recommended vaccination schedules, screening, and common misconceptions. The educational content was structured according to the Health Belief Model constructs, including perceived susceptibility, perceived severity, perceived benefits, perceived barriers, cues to action, and self-efficacy. Participants were invited to return five weeks later for post-intervention assessment.

Sponsors & Collaborators

  • KTO Karatay University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-02-25
Primary Completion
2026-03-31
Completion
2026-03-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07447245 on ClinicalTrials.gov